JP2007534731A - アテローム性動脈硬化症の予防および処置のための医薬組成物 - Google Patents

アテローム性動脈硬化症の予防および処置のための医薬組成物 Download PDF

Info

Publication number
JP2007534731A
JP2007534731A JP2007510084A JP2007510084A JP2007534731A JP 2007534731 A JP2007534731 A JP 2007534731A JP 2007510084 A JP2007510084 A JP 2007510084A JP 2007510084 A JP2007510084 A JP 2007510084A JP 2007534731 A JP2007534731 A JP 2007534731A
Authority
JP
Japan
Prior art keywords
arginine
day
statin
atorvastatin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007510084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534731A5 (enExample
Inventor
クーデルク，レミー
ラスムセン，カロル
マルタン，シャンタル
トリコッテ，ヴィヴィアンヌ
シノベール，リュック
モナー，クリストフ
Original Assignee
ユニベルシテ・ルネ・デカルト・パリ ５
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシテ・ルネ・デカルト・パリ ５ filed Critical ユニベルシテ・ルネ・デカルト・パリ ５
Publication of JP2007534731A publication Critical patent/JP2007534731A/ja
Publication of JP2007534731A5 publication Critical patent/JP2007534731A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007510084A 2004-04-29 2005-04-29 アテローム性動脈硬化症の予防および処置のための医薬組成物 Pending JP2007534731A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0404569A FR2869539B1 (fr) 2004-04-29 2004-04-29 Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
PCT/FR2005/001083 WO2005115371A1 (fr) 2004-04-29 2005-04-29 Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose

Publications (2)

Publication Number Publication Date
JP2007534731A true JP2007534731A (ja) 2007-11-29
JP2007534731A5 JP2007534731A5 (enExample) 2008-05-22

Family

ID=34945560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510084A Pending JP2007534731A (ja) 2004-04-29 2005-04-29 アテローム性動脈硬化症の予防および処置のための医薬組成物

Country Status (7)

Country Link
US (2) US20070219225A1 (enExample)
EP (1) EP1755582B1 (enExample)
JP (1) JP2007534731A (enExample)
ES (1) ES2387890T3 (enExample)
FR (1) FR2869539B1 (enExample)
PT (1) PT1755582E (enExample)
WO (1) WO2005115371A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065028A (ja) * 2014-09-26 2016-04-28 共和薬品工業株式会社 医薬組成物
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
CN102600260A (zh) * 2010-12-24 2012-07-25 漆又毛 一种氨基酸和提取物组合物防治老年性痴呆的药物用途
FR2970414B1 (fr) 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
FR2987270A1 (fr) * 2012-02-29 2013-08-30 Agronomique Inst Nat Rech Produit de combinaison pour le traitement du surpoids et/ou l'amelioration de la silhouette
WO2014139469A1 (en) * 2013-03-15 2014-09-18 Wuhan Qr Science And Technology Development Co. Ornithine- or aspartate-containing compositions and the uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104041A1 (en) * 1982-09-15 1984-03-28 Aktiebolaget Hässle Enzyme inhibitors
JPS59130257A (ja) * 1982-09-15 1984-07-26 アクチェボラゲット・ヘッスレ ポリペプチド同族体
US4749687A (en) * 1984-03-12 1988-06-07 Pfizer Inc. Renin inhibitors containing statine or derivatives thereof
JPH01143898A (ja) * 1987-10-13 1989-06-06 Merck & Co Inc 新規ｃ末端アミノ酸アミドを有するテトラペプチドレニン阻害剤
JP2001523224A (ja) * 1997-04-10 2001-11-20 カエセマイアー，ウェイン，エイチ 血管疾患の治療法及び製剤
US20030114515A1 (en) * 1997-04-10 2003-06-19 Kaesemeyer Wayne H. Therapeutic mixture of HMG-COA reductase inhibitors
WO2003082816A1 (en) * 2002-03-28 2003-10-09 Richter Gedeon Vegyészeti Gyár Rt. New atorvastatin salts and pharmaceutical compositions containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US6028107A (en) * 1997-02-27 2000-02-22 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US20030119714A1 (en) * 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104041A1 (en) * 1982-09-15 1984-03-28 Aktiebolaget Hässle Enzyme inhibitors
JPS59130257A (ja) * 1982-09-15 1984-07-26 アクチェボラゲット・ヘッスレ ポリペプチド同族体
US4749687A (en) * 1984-03-12 1988-06-07 Pfizer Inc. Renin inhibitors containing statine or derivatives thereof
JPH01143898A (ja) * 1987-10-13 1989-06-06 Merck & Co Inc 新規ｃ末端アミノ酸アミドを有するテトラペプチドレニン阻害剤
JP2001523224A (ja) * 1997-04-10 2001-11-20 カエセマイアー，ウェイン，エイチ 血管疾患の治療法及び製剤
US20030114515A1 (en) * 1997-04-10 2003-06-19 Kaesemeyer Wayne H. Therapeutic mixture of HMG-COA reductase inhibitors
WO2003082816A1 (en) * 2002-03-28 2003-10-09 Richter Gedeon Vegyészeti Gyár Rt. New atorvastatin salts and pharmaceutical compositions containing them

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065028A (ja) * 2014-09-26 2016-04-28 共和薬品工業株式会社 医薬組成物
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物

Also Published As

Publication number Publication date
ES2387890T3 (es) 2012-10-03
EP1755582A1 (fr) 2007-02-28
EP1755582B1 (fr) 2012-06-20
FR2869539B1 (fr) 2008-08-08
FR2869539A1 (fr) 2005-11-04
US20080312263A1 (en) 2008-12-18
WO2005115371A1 (fr) 2005-12-08
US20070219225A1 (en) 2007-09-20
PT1755582E (pt) 2012-08-17

Similar Documents

Publication Publication Date Title
US10449154B2 (en) Treatment of NASH with Gemcabene
KR100592842B1 (ko) 알츠하이머병의 치료 방법
EP3478276B1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
US20080312263A1 (en) Pharmaceutical compositions for the prevention and treatment of atherosclerosis
JP2002542191A (ja) グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物
US10849866B2 (en) Methods for inhibiting conversion of choline to trimethylamine (TMA)
EP3522878A1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
JP4813183B2 (ja) Ａｂｃａ１安定化剤
US10751301B2 (en) Methods for inhibiting conversion of choline to trimethylamine (TMA)
RU2372923C2 (ru) Средство, обладающее гиполипидемической и антиатеросклеротической активностью
US20020115728A1 (en) Compositions and methods for treating cardiovascular disorders
JP2010513219A (ja) 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療
UA20096U (en) Procedure for combined medicamentous correction of vascular endothelial dysfunction in patients with diseases of kidneys
Kalra et al. HDL-Cholesterol: The New Target for Treatment
Yu et al. Near term prospects for ameliorating cardiovascular aging
HK1256960A1 (en) Treatment of mixed dyslipidemia
EP3253381A2 (en) Trimethylamine-n-oxide producing agent for treating atheroma formation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111220